Philippe Adam

Sirona Medical took a novel approach to reimagining diagnostic radiology. It's an approach I believe we will see future software companies replicate across the various specialties in medicine. First, they built, from the ground up, an "Epic" like operating system (RadOS) for diagnostic radiology, all in one unified cloud native platform. One system, one service provider...eliminating the need for servers, hardware, etc. This also eliminates the need for radiologists to move in and out of countless different software platforms to accomplish the day to day tasks associated with practicing medicine. They then built assistive AI programs into system, making physicians faster, and more effective. And finally, they allowed top 3rd party AI vendors to build the kind of diagnostic AI programs on top of their platform, that are the future product that radiology will provide. This is the path less traveled for sure. It's expensive, and takes a considerable amount of time. But the impact these types of platforms will have on physicians, patients, and the system as a whole is profound. I believe strongly that what Sirona Medical has done will revolutionize this space. Over the next couple weeks, I will post some additional clips to further inform the market on why what they have done is so unique...and just how transformative this technology will be. In the interim, episode 46 of The Bleeding Edge of Digital Health Podcast is now up for viewing on all the major podcast directories, and our YouTube channel (links in comments). Thank you Cameron Andrews for joining on the show, and sharing the incredible tech you and your team have built! Bill Corsten Greg Stock David Paik Kathryn Kovalenko Aidan Andrews Raghavendra Nyamagoudar Nathan Ayers Chris Calder Jon Gallez Francisco Gimenez Perry Kaneriya, MD, MBA Patrice JC Nedelec 🇫🇷🇺🇸🇺🇦 Daniel C. Liem Samir Mehta Kaitlin Daugherty Mark D. Longo, Ph.D. Mike McCormick Ryan Dougherty Fred Ong Tanner Trombly Vijay Yeluri Adam Prater Alex Mc Vey #radiology #medtech #digitalhealth

58

8 Comments

I think virtual-first healthcare plans are the future of healthcare. I just finished reading about Virtual Blue’s early results in Fierce Healthcare from Paige Minemyer. Enrollees are increasingly visiting primary care providers and reducing emergency care visits in just one year. But to get results like that, people have to use it. Virtual care is only as good as its ability to engage patients. That’s why at TytoCare, we’ve made our Tyto Engagement Labs a top priority.   Virtual-first plans are the future. TytoCare is ready to make it happen now.  #telehealth #healthcare  #healthcareinnovation

32

1 Comment

Based on what we've seen from the introduction of other technologies (digital and analog) into medicine and other industries over many decades, this is a dialogue/negotiation/argument that we're going to be seeing a LOT of in the coming years: Kaiser's nurses: "Human expertise and clinical judgment are the only ways to ensure safe, effective, and equitable nursing care," stated Cathy Kennedy, RN, a nurse at Kaiser Permanente Roseville (Calif.) Medical Center and a president of the state nursing association. "We know there is nothing inevitable about AI's advancement into healthcare. No patient should be a guinea pig and no nurse should be replaced by a robot." Kaiser management: "At Kaiser Permanente, AI tools don't make medical decisions — our physicians and care teams are always at the center of decision-making with our patients," the spokesperson said. "We believe that AI may be able to help our physicians and employees and enhance our members' experience. As an organization dedicated to inclusiveness and health equity, we ensure the results from AI tools are correct and unbiased; AI does not replace human assessment." I can't comment about the specifics of the deployment of clinical AI at Kaiser Permanente. However, I will say that the future success of healthcare outcomes will depend heavily on a successful negotiation of these differing perspectives between clinical professionals and "the bean counters."

11

2 Comments

Very interesting article on enabling technologies in Orthopedics... the proliferation (arms race) of Robotics (big and small), AR, AI and other technologies will have some BIG winners and a lot of "whatever happened to...". My good friend Sharat Kusuma, MD, FAAOS and Zimmer Biomet Chief Innovation Officer Nitin G. are both interviewed. Interesting perspective around the potential improvement (needs study) for lower volume Surgeons who typically are working in institutions who are less apt to purchase or ASC where any additional cost or time is less likely to be considered. https://lnkd.in/ggBhHQWH #vestiaconsulting #orthopedics #orthopedicsurgery Vestia Personal Wealth Advisors #DoctorCFO #wealththatmatters

8

2 Comments

Medtech capital raising: a summary of what I'm reading, hearing, and seeing. Would love to hear your opinion. Reading There’s cautious optimism. Headlines are starting to reflect a turning point, as highlighted in the Financing Outlook article in the latest issue of The Lens. Hearing In my conversations with Medtech venture investors, I’m hearing a consistent message: confidence is growing, though cautiously. Momentum is building, and we’ll likely see an increase in capital deployment. Seeing (most important) The most compelling indicator isn’t just what I’m reading or hearing—it’s what I’m seeing. Investors are showing up in force to look at deals. The sheer volume and quality of investors and strategics attending LSI USA '25 point to a strong appetite for Medtech investing and dealmaking over the next year. Here’s a small snapshot of the 200 investors & strategics already committed to our next event (pacing for well over 400 total). If you haven’t secured your spot, now’s the time. What is your outlook on the capital raising outlook for the next 12 months?

99

10 Comments

Unveiling the Potential of #GenerativeAI in #Orthopedics https://lnkd.in/g35gkKpE #AR #CustomImplants #diagnostics #healthcare #MedicalImaging #PatientData #PatientSpecific #PersonalizedTreatment #PredictiveAnalytics #RoboticSurgery #SurgicalNavigation #SurgicalPlanning #VR

2

I will be at DeviceTalks West in Santa Clara on Oct. 15-17 and would love to connect with you. It’s the perfect spot to connect with #medtech professionals about the unique challenges Medtech players face, whether they’re #startups or established #medicaldevice organizations. Nunex is Medtech Momentum Multiplied. We orchestrate the services you need and when you need them: Holistic Expertise: Our seasoned team covers all aspects of Medtech development, from regulatory compliance to market access strategy. Tailored Solutions: We customize our services to meet your needs at every growth stage. Orchestrated Success: We don't just provide services; we combine what you need and when you need it for maximum impact. If you want to accelerate your growth, please reach out to me while I'm at Device Talks West so we can meet! #medicaldevice #regulatory #marketaccess #nunex #medtechmomentummultiplied

20

Investment and innovation, not export controls, will ensure American leadership in deep tech. Commerce Secretary Gina Raimondo via The Wall Street Journal: “Trying to hold China back is a fool’s errand,” “The only way to beat China is to stay ahead of them,”she said. “We have to run faster, out innovate them. That’s the way to win.” https://lnkd.in/gPqtU7ak

18

1 Comment

As Kimberly Powell puts it - Generative AI is poised to impact healthcare more profoundly than ANY other area of life. Everything from accelerating drug discovery to enhancing patient diagnostics and postoperative care is on the table. The only roadblock in front of us is the speed and efficiency with which we can implement AI on scale. Could Nvidia be the answer to these teething issues? #AIHealthcare #Healthcare #NvidiaAI #GenerativeAI #MedicalInnovation

2

I recently had the pleasure of meeting Cathy Friedman, Executive Venture Partner at Google Ventures, at Fortune Brainstorm Health 2024. Our discussion primarily focused on the transformative potential of AI within the US healthcare system, as well as GV' keen interest in supporting companies that leverage technology to advance healthcare through AI. Google’s goal is to foster the growth of these innovative AI technologies, ultimately making the US healthcare system more efficient, and cost-effective. During our conversation, I had the opportunity to discuss Cognos' SINNAIS AI-driven implantable pump and its potential application for offering new and promising cure modality to improve Alzheimer cure outcome using Cognos' concept of Brain Microdialysis of CSF, a patented (https://lnkd.in/gx2z_mRY) technology. Alzheimer's disease affects over 50 million people worldwide, including about 5 million patients in the US, costing the US healthcare system over $305 billion annually. One of the foremost challenges facing pharmaceutical companies is effectively delivering drugs to the brain. Despite massive investments and efforts by pharmaceutical companies, utilizing countless scientists and millions in research, drugs often struggle to penetrate the brain due to the blood-brain barrier (BBB). SINNAIS will be an implantable pump that delivers drugs directly to the brain intraventricularly, helping the drugs bypass the BBB. Managing and finding a cure for millions of Alzheimer's patients will not be the work of a few companies or institutions; it will be the work of the nation. Cognos recognizes this challenge and is in the process of producing a white paper to introduce Cognos brain microdialysis of CSF concept to academic medical communities, physicians who are opinion leaders in the field, and private corporations whose technologies will complement and support tracking and monitoring patients using SINNAIS using AI. This also includes government agencies such as DARPA and the investment communities. Cognos anticipates that once the value of brain dialysis of CSF is fully understood and realized through supporting clinical data and SINNAIS is available commercially, Alzheimer's patients may have the opportunity to enjoy prolonged life with quality. Cognos plans to build a coalition of some of the most prominent and formidable CEOs whose companies’ technologies can complement SINNAIS to reach commercialization and make a positive impact in improving the treatment of Alzheimer's. Among these leaders, Cognos plans to reach out to BILL GATES, JEFF BEZOS, LARRY PAGE, SERGEY BRIN, JENSEN HUANG, DAVID RUBENSTEIN, and a host of other billionaires who will be invited to support the initiative, provide strategic financial resources, and help pave the way for finding a viable solution to this unmet need.

10

MedTech is HealthTech - but not all HealthTech is MedTech. 🤨 MedTech is a synonym for Medical Devices & Diagnostics ❗️ Words. Buzzwords. Terms. Definitions. Yet another 🗣️ issue. Outsiders often confuse MedTech with HealthTech, pharmaceuticals, biotechnology, and consumer health solutions. Those who have worked with medical devices understand the differences. But for most people, this is yet another buzzword to learn. Patients don't even realize that most of the technology used in clinical settings are regulated products - just like pharmaceuticals. We take it for granted. I've met several founders who don't realize they are developing a solution that must comply with MedTech regulations before it can be used or sold to anyone I've also met investors who speak of HealthTech, but when, in fact, they only work with non-regulated DigitalHealth or lifestyle management solutions and don't want to touch "regulated products" due to the (implied) high risk. But what's the fun in that? 😎 Medical technology is one of the most exciting industries of our age. The potential to create life-changing medical solutions for all demographics is so rewarding. Yes, the pathway to success is steep and dangerous, but the risk is worth it. That's why so many do it. Take the risk 🌟 and create a medical device that's safe and makes a significant clinical impact. It might save somebody's life❤️‍🩹 #medtech #medicaldevices #healthtech

39

4 Comments

This upcoming Friday I will have my Year in Review - 2024 and I will discuss the evolving models in medtech that support the critical development of emerging technologies and the ability to bring those technologies to patients via acquisition, rollup into private equity, or entry into the public markets. One of those successful models is Shifamed that has developed a fascinating and successful playbook. Amr Salahieh and I recently discussed the unique structure of Shifamed companies and the benefits to the market.

98

5 Comments

Next (few) years ahead will get rather interesting in Medtech. Increasing uncertainty, or lower predictability doesn't lead to higher inaccuracy in planning. In fact, one should double down and build scenarios. Folks who plan well shall be able to allocate capital sensibly and deliver above average rate of growth.

112

2 Comments

Getting amazing contract manufacturing partners is everything, but navigating the RFQ process is hard. Learn how to ace this process in the new pod episode

35

5 Comments

The success of the MedTech industry in Israel is inherently tied to the mentality of its founders in 1948, that they could make Something from Nothing, as I discuss in this clip. We had a lot of fun reminiscing about the MedTech Mission to Israel with Joe Mullings and Nicole Ager of Dragonfly - A TMG Company, along with Adam Rosenwach, Avi Fischer, David Hochman and Tal Wenderow. https://lnkd.in/e5spq4SM

49

2 Comments

NVIDIA has the opportunity to be the most impactful player in medtech / healthtech, and healthcare. More than Johnson & Johnson, Medtronic or any of the other billion dollar per year companies. NVDIA is aiming its attention and assets at the healthcare market which is north of $600B in the US and more than $12 trillion worldwide. The question is though ....."Are the large strategics currently staffed and designed to execute on "developing the box and the business model" required in healthcare that NVDIA can execute on? Which one will be the first to burn away that which is holding them hostage to legacy products and solutions in order to execute on the road ahead? Who will have the courage to create the off balance sheet entity that will protect their precious stock price and go legitimately "pot in" on the next generation of healthcare? I seriously doubt that NVDIA will wait based on the current dynamics in the marketplace. When does NVDIA assemble the minds that are in medtech today who are quietly restrained by corporate playbooks and create their own medtech/healthtech company?

298

54 Comments

good to see 'remote patient management' (I prefer this term to 'monitoring') gaining investment traction from big names. It is however worth mentioning that only a very small portion of home care patients truly require 'continuous monitoring'. Also here, the concept is evolving to near-time monitoring and proactive prevention. Next is to see payors supporting this new stream outside of the US with focus on wellbeing as opposed to on 'acvoiding readmissions'. The latter being just another pothole in the sick care process. BARMER in #Germany is leading in this context.

1

I am excited to lead a panel discussion with CEOs titled “Cash, Crew, and Commercialisation: A Startup's Journey to Success” at the LSX - partnering for Life Science eXecutives Medtech Leaders World Congress USA in Boston September 12-13th. LSX equity partners recently shared what they were most interested to understand about potential companies they would consider investing in after the product value proposition relevant to Leadership, Talent, and Strategy: 1. Does the company already have a strong RA/QA Strategy and/or Leader in place? 2. Does the company already have a strong Reimbursement Strategy and/or Leader in place? 3. Does the company already have a strong Commercial Strategy and/or Leader in place? If the answer is no to any of these questions, then they wouldn’t be interested in investing. The data is clear on why companies succeed or fail and it starts #Leadership. Certainly, companies must have a viable product or service that improves patient outcomes, increases patient access, and improves efficiency in a profitable fashion within the healthcare system. However, leadership relevant to #Mission & #Vision, company alignment or misalignment, and hiring the right or wrong Talent that fits the culture are always significant factors in determining success or failure. Strong leadership with a personal #WHY that matches the company Mission increases employee engagement with less wasted resources and increases the retention rates of your #ParetoPrinciple amplifiers. #Hireforculture #costofmishires #Medtech #Lifesciences #QualityMatters #RegulatoryStrategy #TalentManagement

13

1 Comment